Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Kaletra”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Study completedNCT00148759
What this trial is testing

Kaletra Sex/Gender Pharmacokinetics (PK) Study

Who this might be right for
HIV Infections
Emory University 23
Post-approval studies (Phase 4)UnknownNCT04350684
What this trial is testing

Umifenovir in Hospitalized COVID-19 Patients

Who this might be right for
COVID-19
Shahid Beheshti University of Medical Sciences 40
Early research (Phase 1)Study completedNCT00697892
What this trial is testing

Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations

Who this might be right for
HIV InfectionsMalaria
Fran Aweeka 38
Testing effectiveness (Phase 2)Study completedNCT00075231
What this trial is testing

A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

Who this might be right for
HIV Infections
Abbott 150
Post-approval studies (Phase 4)Ended earlyNCT01031849
What this trial is testing

Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir

Who this might be right for
HIV Infections
Ines Perez 7
Large-scale testing (Phase 3)Ended earlyNCT00144833
What this trial is testing

Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

Who this might be right for
HIV-1
GlaxoSmithKline 150
Post-approval studies (Phase 4)Study completedNCT00810108
What this trial is testing

Lopinavir/Ritonavir (Kaletra) PK in Children

Who this might be right for
HIV/AIDS TreatmentHIV Infections
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 12
Testing effectiveness (Phase 2)Study completedNCT02415985
What this trial is testing

Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly

Who this might be right for
HIVTuberculosis
The HIV Netherlands Australia Thailand Research Collaboration 40
Post-approval studies (Phase 4)Ended earlyNCT00981318
What this trial is testing

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

Who this might be right for
HIV InfectionsAcquired Immunodeficiency Syndrome
Rodwick, Barry M., M.D. 3
Large-scale testing (Phase 3)Study completedNCT00234910
What this trial is testing

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients

Who this might be right for
HIV Infection
Abbott 152
Large-scale testing (Phase 3)UnknownNCT00025727
What this trial is testing

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

Who this might be right for
HIV Infections
GlaxoSmithKline 330
Not applicableStudy completedNCT00357552
What this trial is testing

Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy

Who this might be right for
HIV Infections
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections 123
Post-approval studies (Phase 4)Ended earlyNCT00234962
What this trial is testing

Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy

Who this might be right for
HIV Infection
Abbott 200
Testing effectiveness (Phase 2)UnknownNCT01663168
What this trial is testing

EARNEST Rifabutin Pharmacokinetics (PK) Substudy

Who this might be right for
HIVTuberculosis
Justine Boles 140
Not applicableLooking for participantsNCT03603977
What this trial is testing

Simplified Treatment of Anti-retrovirus in China (C-STAR)

Who this might be right for
HIV/AIDS
Guangzhou 8th People's Hospital 600
Large-scale testing (Phase 3)Study completedNCT02227238
What this trial is testing

Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment

Who this might be right for
HIV Infections
ViiV Healthcare 627
Early research (Phase 1)UnknownNCT01259219
What this trial is testing

Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra

Who this might be right for
Children With Confirmed HIV InfectionReceiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard DoseSuccessfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
Harriet Shezi Children's Clinic 40
Not applicableStudy completedNCT01383005
What this trial is testing

Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)

Who this might be right for
Human Immunodeficiency Virus Infection
AbbVie (prior sponsor, Abbott) 97
Large-scale testing (Phase 3)Study completedNCT00140751
What this trial is testing

Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients

Who this might be right for
HIV Infections
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba 186
Large-scale testing (Phase 3)Study completedNCT00358917
What this trial is testing

Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

Who this might be right for
Human Immunodeficiency Virus Infections
Abbott 599
Next Page